- Conditions
- Major Depressive Disorder
- Interventions
- CYB003, Psychological Support, Placebo
- Drug · Behavioral
- Lead sponsor
- Cybin IRL Limited
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 35 more
Condition Directory
Depression clinical trials
Directory of U.S. ClinicalTrials.gov public records for Depression. Browse Depression recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
5328
Shown on this page
12
Current sort
Recently updated
Condition scope
Depression
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Depression studies are organized in the registry
Most records use the formal term “major depressive disorder” or MDD rather than “depression” alone, and “treatment-resistant depression” (TRD) labels a distinct, sizable subset. The portfolio includes many behavioral, digital, and device interventions, so the intervention and study-type filters do real work here.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 205–216 of 5,328 matching trials for Depression.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Depressive Disorder, Major
- Interventions
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Redlands, California • San Diego, California • Marietta, Georgia + 4 more
- Conditions
- Depression
- Interventions
- Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Depression, Caregivers, Dementia
- Interventions
- WeACT
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
- Interventions
- TNX-102 SL, Placebo sublingual tablet
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Buena Park, California • Chino, California + 24 more
- Conditions
- Bipolar Depression
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 56
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
- Conditions
- Opioid Use Disorder, Major Depressive Disorder (MDD)
- Interventions
- Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
- Device
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Depressive Disorder, Depressive Symptoms
- Interventions
- Ash, Brief Therapist-Delivered Telehealth
- Behavioral
- Lead sponsor
- Slingshot AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
- Interventions
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Device
- Lead sponsor
- Qbtech AB
- Industry
- Eligibility
- 6 Years to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Sleep, Fatigue, Anxiety, Cancer, Depression
- Interventions
- Melatonin, Placebo for Melatonin, Methylphenidate
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
About this Depression clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Depression as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Depression.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Depression.